Second unanimous FDA adcomm vote boosts bluebird bio
pharmaphorum
JUNE 12, 2022
Thursday saw the Cellular, Tissue and Gene Therapies advisory committee back elivaldogene autotemcel (eli-cel) for cerebral adrenoleukodystrophy (CALD) – see our report here – and the following day it was the turn of betibeglogene autotemcel (beti-cel) for beta thalassaemia. The verdict on beti-cel is due from the agency by 19 August.
59 
Let's personalize your content